NKTX Nkarta, Inc.Stock Price & Overview
$6.50
Charts
Quant Ranking
NKTX Analysis
NKTX News
Latest Headlines
Ratings Summary
People Also Follow
Similar to NKTX
ETFs Holding NKTX
NKTX Company Profile
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Revenue
NKTX Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
NKTX Ownership
NKTX Peers
Risk
Technicals
NKTX SEC Filings
Press Releases
NKTX Income Statement
NKTX Balance Sheet
NKTX Cash Flow Statement
NKTX Long Term Solvency
Discover More
You may be interested in: